Insulet (NASDAQ:PODD) Given Buy Rating at BTIG Research

BTIG Research reaffirmed their buy rating on shares of Insulet (NASDAQ:PODD) in a report released on Thursday morning,Benzinga reports. BTIG Research currently has a $370.00 target price on the medical instruments supplier’s stock.

PODD has been the topic of a number of other research reports. Royal Bank Of Canada lifted their price target on shares of Insulet from $365.00 to $370.00 and gave the stock an “outperform” rating in a report on Friday, November 7th. Oppenheimer raised their price objective on shares of Insulet from $324.00 to $365.00 and gave the stock an “outperform” rating in a research report on Monday, September 8th. Jefferies Financial Group raised their price target on shares of Insulet from $375.00 to $400.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. The Goldman Sachs Group increased their price objective on shares of Insulet from $375.00 to $388.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Finally, Leerink Partners increased their price objective on Insulet from $355.00 to $385.00 and gave the stock an “outperform” rating in a report on Friday, November 7th. One research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $374.10.

Insulet Price Performance

PODD stock traded up $0.03 during midday trading on Thursday, reaching $332.70. The company had a trading volume of 405,841 shares, compared to its average volume of 716,610. The company has a market capitalization of $23.40 billion, a price-to-earnings ratio of 101.12, a price-to-earnings-growth ratio of 2.64 and a beta of 1.39. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. Insulet has a 1-year low of $230.05 and a 1-year high of $353.50. The stock has a 50 day moving average price of $323.58 and a 200-day moving average price of $312.03.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.13 by $0.11. The company had revenue of $521.70 million for the quarter, compared to analyst estimates of $678.70 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The company’s revenue for the quarter was up 29.9% compared to the same quarter last year. During the same quarter last year, the company posted $1.08 EPS. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Equities research analysts expect that Insulet will post 3.92 earnings per share for the current year.

Insider Buying and Selling

In related news, SVP Laetitia Cousin sold 797 shares of Insulet stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the sale, the senior vice president directly owned 3,890 shares in the company, valued at $1,356,870.90. This trade represents a 17.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Prem Singh sold 687 shares of the company’s stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the sale, the senior vice president owned 3,456 shares of the company’s stock, valued at $1,200,925.44. This trade represents a 16.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 0.39% of the company’s stock.

Institutional Investors Weigh In On Insulet

A number of large investors have recently modified their holdings of the company. Inspire Investing LLC raised its stake in shares of Insulet by 299.5% during the first quarter. Inspire Investing LLC now owns 4,119 shares of the medical instruments supplier’s stock valued at $1,082,000 after purchasing an additional 3,088 shares in the last quarter. Illinois Municipal Retirement Fund increased its position in Insulet by 41.3% in the 2nd quarter. Illinois Municipal Retirement Fund now owns 12,030 shares of the medical instruments supplier’s stock worth $3,780,000 after purchasing an additional 3,514 shares during the last quarter. Gradient Investments LLC acquired a new position in Insulet in the second quarter worth approximately $17,429,000. Goldman Sachs Group Inc. raised its holdings in Insulet by 1.9% during the first quarter. Goldman Sachs Group Inc. now owns 579,302 shares of the medical instruments supplier’s stock valued at $152,130,000 after buying an additional 10,628 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC acquired a new stake in shares of Insulet in the second quarter worth about $1,081,000.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.